GoodRx Holdings, Inc. (NASDAQ:GDRX) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET
Company Participants
Aubrey Reynolds - Director of Investor Relations
Scott Wagner - Interim Chief Executive Officer
Karsten Voermann - Chief Financial Officer
Mike Walsh - President & EVP, Prescription Marketplace
Conference Call Participants
Charles Rhyee - TD Cowen
Lisa Gill - JPMorgan
John Ransom - Raymond James
Stephanie Davis - Barclays
Jailendra Singh - Truist Securities
Scott Schoenhaus - KeyBanc
Stan Berenshteyn - Wells Fargo Securities
Kevin Caliendo - UBS
Allen Lutz - Bank of America
Daniel Grosslight - Citi
Jack Wallace - Guggenheim Securities
George Hill - Deutsche Bank
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Rx Second Quarter 2024 Earnings Call. As a reminder, today's conference call is being recorded.
I would now like to introduce your host for today's call, Aubrey Reynolds, Director of Investor Relations. Ms. Reynolds, you may begin.
Aubrey Reynolds
Thank you, operator. Good morning, everyone, and welcome to GoodRx's earnings conference call for the second quarter 2024. Joining me today are Scott Wagner, our Interim Chief Executive Officer; Karsten Voermann, our Chief Financial Officer; and Mike Walsh, our President and EVP of Prescription Marketplace.
The team is not in the same location for today's call, but we will do our best to make the Q&A portion as seamless as possible for our audience. Before we begin, I'd like to remind everyone that this call will contain forward-looking statements. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding management's plans, strategies, goals and objectives, our market opportunity, our anticipated financial performance, underlying trends in our business and industry, including ongoing changes in the pharmacy ecosystem, our value proposition, our long-term growth prospects, our hybrid retail direct and PBM contracting approach, collaborations and partnerships with third parties, including our integrated savings program and our capital allocation priorities.
These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors. These factors may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
Factors discussed in the Risk Factor section of our Annual Report on Form 10-K for the year ended December 31, 2023, and our other financial filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made on this call. Any such forward-looking statements represent management estimates as of the date of this call, and we disclaim any obligation to update these statements even if subsequent events cause our views to change.